NCT00329693
Completed
Phase 2
A Randomised, Double-blind, Parallel Groups, Dose-finding, Placebo-controlled, Multi-centre, Proof of Concept Study Assessing the Effect of 3-wk Treatment With 1 of 3 Oral Doses of Quinagolide & Placebo in Preventing Ovarian Hyperstimulation Syndrome in Women Undergoing Controlled Ovarian Hyperstimulation.
Overview
- Phase
- Phase 2
- Intervention
- Norprolac
- Conditions
- Ovarian Hyperstimulation Syndrome
- Sponsor
- Ferring Pharmaceuticals
- Enrollment
- 182
- Locations
- 7
- Primary Endpoint
- OHSS
- Status
- Completed
- Last Updated
- 14 years ago
Overview
Brief Summary
Women included in this study are undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART) and present with signs of moderate risk of developing OHSS.
Detailed Description
No data to be entered.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
1
Daily Tablets Dosing
Intervention: Norprolac
2
Daily Tablets Dose
Intervention: Norprolac
3
Daily Tablets Dosing
Intervention: Norprolac
4
Daily Tablets Dosing
Intervention: Norprolac
Outcomes
Primary Outcomes
OHSS
Time Frame: 41 days after hCG injection
Study Sites (7)
Loading locations...
Similar Trials
Completed
Phase 1
Study in Healthy Young Women to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of VilaprisanClinical Trial, Phase INCT02262663Bayer70
Completed
Phase 4
Role of Myo-inositol and D-chiro-inositol on Oocyte QualityInfertilityNCT01338844AGUNCO Obstetrics and Gynecology Centre
Active, not recruiting
Phase 2
A Trial of Vigil for Participants With Ovarian CancerOvarian CancerOvarian NeoplasmsNCT02346747Gradalis, Inc.92
Completed
Phase 4
CONSORT Randomized Controlled Trial in Assisted Reproductive TechnologyInfertilityNCT00829244Merck KGaA, Darmstadt, Germany200
Completed
Phase 3
Casodex vs Placebo in Non-Metastatic Early Prostate CancerNon-Metastatic Prostate CancerNCT00672282AstraZeneca1,218